Myeloid-derived suppressor cells: Are they involved in gestational diabetes mellitus?

Am J Reprod Immunol. 2023 Jul;90(1):e13711. doi: 10.1111/aji.13711. Epub 2023 May 8.

Abstract

Gestational diabetes mellitus (GDM) is currently the most common metabolic complication during pregnancy, with an increasing prevalence worldwide. Maternal immune dysregulation might be partly responsible for the pathophysiology of GDM. Myeloid derived suppressor cells (MDSCs) are a heterogeneous population of cells, emerging as a new immune regulator with potent immunosuppressive capacity. Although the fate and function of these cells were primarily described in pathological conditions such as cancer and infection, accumulating evidences have spotlighted their beneficial roles in homeostasis and physiological conditions. Recently, several studies have explored the roles of MDSCs in the diabetic microenvironment. However, the fate and function of these cells in GDM are still unknown. The current review summarized the existing knowledges about MDSCs and their potential roles in diabetes during pregnancy in an attempt to highlight our current understanding of GDM-related immune dysregulation and identify areas where further study is required.

Keywords: gestational diabetes mellitus; immunoregulation; maternal-fetal; myeloid derived suppressor cells.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Diabetes, Gestational* / metabolism
  • Female
  • Homeostasis
  • Humans
  • Myeloid-Derived Suppressor Cells*
  • Neoplasms*
  • Pregnancy
  • Tumor Microenvironment